FDA approves Direct Biologics to proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial

Apr 22, 2022

Austin (Texas) [US], April 22 (ANI/PRNewswire): Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the...

DCGI approves Itolizumab injection for restricted emergency use on COVID-19 patients

Jul 10, 2020

New Delhi [India], July 11 : The Drug Controller General of India (DCGI) granted its permission to Itolizumab injection for the restricted emergency use...

Medica Superspecialty Hospital breathes new life to 60 yr. old ECMO COVID positive physician after 60 days in hospital

Aug 10, 2020

Kolkata (West Bengal) [India], Aug 10 (ANI/BusinessWire India): Medica Group of Hospitals, the largest private hospital chain in Eastern India, has successfully treated and...

Biocon's drug Itolizumab gets DCGI nod for use in moderate to severe Covid-19 patients

Jul 11, 2020

Bengaluru (Karnataka) [India], July 11 : Biopharmaceutical major Biocon Ltd said on Saturday it has received approval from the Drugs Controller General of India...

FDA grants Direct Biologics regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS

Apr 13, 2022

Austin (Texas) [US], April 13 (ANI/PRNewswire): Direct Biologics, an innovative biotechnology company with a groundbreaking extracellular vesicle (EV) platform drug technology, announced that the...

Direct Biologics reveals successful outcomes from EXIT COVID-19 Phase II Clinical Trial

Apr 06, 2022

Austin [Texas], April 6 (ANI/PRNewswire): Direct Biologics, a regenerative biotechnology company with a lifesaving mesenchymal stem cell (MSC) derived extracellular vesicle (EV) platform technology,...